PubMed
An NNMT inhibitor activates oxidative metabolism and reduces obesity in mice
Neelakantan H, Vance V, Wang H, et al. Nat Commun. 2019
GLP-1 & MetabolicResearch OnlyC
5-Amino-1MQ
NNMT Inhibitor
Small-molecule NNMT inhibitor often discussed with metabolic protocols; investigational.
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 97
- Activity
- 86
Overall check-ins
Trackers & reports
Overview
About 5-Amino-1MQ
Small-molecule NNMT inhibitor often discussed with metabolic protocols; investigational.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Research Only
- Also known as
- NNMT Inhibitor
- Self-reports
- 43
Community
What 43 users report
43 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 94% · Mixed 6% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
158
Recovery
158
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
9
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
0.2–0.4 mg
1
0.4–0.6 mg
2
1–2 mg
21
5+ mg
134
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 86 days · Based on 28 repeat reporters
Research
Sources (3)
- Wiki study page →Source
- Wiki study page →Source
PubMed
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Heide J, Bilecz AJ, Patnaik S, et al. Nature. 2025
- Wiki study page →Source
PubMed
Exploring NNMT: from metabolic pathways to therapeutic targets
Park J, Shin EJ, Kim TH, et al. Archives of pharmacal research. 2024
Tools
Explore more
Explore
More ways to learn about 5-Amino-1MQ from observational PeptIQ data.
Compare with
Help
Frequently asked
What do PeptIQ users report about 5-Amino-1MQ?
This page summarizes 43 anonymized self-reports from PeptIQ users who track 5-Amino-1MQ, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for 5-Amino-1MQ?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for 5-Amino-1MQ?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is 5-Amino-1MQ safe to use?
This wiki does not assess safety or recommend use. 5-Amino-1MQ is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of 5-Amino-1MQ?
This wiki summarizes observational community reports and linked citations for 5-Amino-1MQ. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for 5-Amino-1MQ for study-level context — not medical advice.
What is the legal status of 5-Amino-1MQ?
5-Amino-1MQ is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of 5-Amino-1MQ?
Safety data quality for 5-Amino-1MQ varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on 5-Amino-1MQ?
This page links 3 sources for 5-Amino-1MQ. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.